サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：皮膚がん診断の世界市場：予測（2023年～2032年）
市場調査レポート
商品コード
1294755

皮膚がん診断の世界市場：予測（2023年～2032年）

Global Skin Cancer Diagnostics Market Forecast 2023-2032
出版日: | 発行: Inkwood Research | ページ情報: 英文 229 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
皮膚がん診断の世界市場：予測（2023年～2032年）
出版日: 2023年06月16日
発行: Inkwood Research
ページ情報: 英文 229 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の皮膚がん診断の市場規模は、2023年～2032年の予測期間中に7.13％のCAGRで拡大すると予測されています。市場成長の主な促進要因は、皮膚がん有病率の増加、皮膚がん診断・治療に対する意識の高まり、皮膚がん診断製品の技術進歩です。

当レポートでは、世界の皮膚がん診断市場について調査し、市場の概要とともに、タイプ別、性別、スクリーニングタイプ別、地域別の動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査範囲と調査手法

第2章 エグゼクティブサマリー

第3章 市場力学

  • 主な促進要因
  • 主な抑制要因

第4章 主要な分析

  • 親市場分析
  • 主要な市場動向
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 市場集中分析
  • バリューチェーン分析

第5章 タイプ別市場

  • 黒色腫
  • 非黒色腫

第6章 性別市場

  • 男性
  • 女性

第7章 スクリーニングタイプ別市場

  • 皮膚生検
  • 皮膚鏡検査
  • リンパ節
  • 生検画像検査
  • 血液検査

第8章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第9章 競合情勢

  • 主要な戦略的展開
  • 企業プロファイル
    • AMLO BIOSCIENCES LIMITED
    • BIOMERIEUX SA
    • CASTLE BIOSCIENCES INC
    • DERMLITE LLC
    • DERMTECH INC
    • F. HOFFMANN-LA ROCHE LTD
    • MICHELSON DIAGNOSTICS LTD
    • NERACARE GMBH
    • SKYLINEDX BV
    • VERISKIN INC
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - SKIN CANCER DIAGNOSTICS
  • TABLE 2: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 4: GLOBAL MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: GLOBAL MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 6: GLOBAL NON-MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: GLOBAL NON-MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 8: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 10: GLOBAL MALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 11: GLOBAL MALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 12: GLOBAL FEMALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 13: GLOBAL FEMALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 14: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 15: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 16: GLOBAL SKIN BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 17: GLOBAL SKIN BIOPSY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 18: GLOBAL DERMATOSCOPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 19: GLOBAL DERMATOSCOPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 20: GLOBAL LYMPH NODE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 21: GLOBAL LYMPH NODE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 22: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 23: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 24: GLOBAL BLOOD TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 25: GLOBAL BLOOD TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 26: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 27: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 28: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 29: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 30: KEY PLAYERS OPERATING IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
  • TABLE 31: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 32: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 33: KEY PLAYERS OPERATING IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
  • TABLE 34: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 35: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 36: KEY PLAYERS OPERATING IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
  • TABLE 37: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 38: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
  • TABLE 39: KEY PLAYERS OPERATING IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
  • TABLE 40: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 41: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
  • FIGURE 4: GROWTH PROSPECT MAPPING FOR EUROPE
  • FIGURE 5: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
  • FIGURE 6: GROWTH PROSPECT MAPPING FOR MEXICO
  • FIGURE 7: MARKET CONCENTRATION ANALYSIS
  • FIGURE 8: VALUE CHAIN ANALYSIS
  • FIGURE 9: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
  • FIGURE 10: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2032 (IN $ MILLION)
  • FIGURE 11: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2032 (IN $ MILLION)
  • FIGURE 12: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022
  • FIGURE 13: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2032 (IN $ MILLION)
  • FIGURE 14: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2032 (IN $ MILLION)
  • FIGURE 15: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022
  • FIGURE 16: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2032 (IN $ MILLION)
  • FIGURE 17: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2032 (IN $ MILLION)
  • FIGURE 18: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2032 (IN $ MILLION)
  • FIGURE 19: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2032 (IN $ MILLION)
  • FIGURE 20: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2032 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 22: UNITED STATES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 23: CANADA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 24: EUROPE SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 25: UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 26: GERMANY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 27: FRANCE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 28: ITALY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 29: SPAIN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 30: NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 31: BELGIUM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 32: POLAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 33: REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 34: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 35: CHINA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 36: JAPAN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 37: INDIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 38: SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 39: INDONESIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 40: THAILAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 41: VIETNAM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 42: AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 43: REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 44: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)
  • FIGURE 45: LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
  • FIGURE 46: MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
目次
Product Code: 51891

KEY FINDINGS

The global skin cancer diagnostics market is projected to grow with a CAGR of 7.13% during the forecast period 2023-2032. The market's growth is mainly fueled by the increasing prevalence of skin cancer, the surging awareness about skin cancer diagnosis & treatment, as well as technological advancements in skin cancer diagnostic products.

MARKET INSIGHTS

Skin cancer diagnostics entails the segment of the healthcare industry that covers various technologies, products, and services associated with the diagnosis, assessment, and detection of skin cancer. Skin cancer diagnostics methods generally include an amalgamation of visual inspection, dermoscopy, clinical examination, and tissue samples' histopathological analysis.

Advanced technologies, including artificial intelligence (AI), are being widely utilized for the development of innovative skin cancer detection systems, capable of identifying the condition more efficiently and accurately compared to conventional methods. For instance, DermTech developed an AI-powered skin cancer detection system termed Athena. The system has demonstrated high accuracy in terms of identifying skin cancer. As a result, such cutting-edge technological advancements in skin cancer diagnostic products are projected to play an essential role in fueling the global skin cancer diagnostics market growth during the forecast period.

REGIONAL INSIGHTS

The global skin cancer diagnostics market growth analysis covers the study of North America, Europe, Asia-Pacific, and Rest of World. The market in North America is set to capture the highest revenue share by 2023. The regional market's growth is propelled by key factors, such as significant investments in the research & development of skin cancer diagnostics products by major players as well as the increasing prevalence of skin cancer.

COMPETITIVE INSIGHTS

The industrial rivalry in the global skin cancer diagnostics market is expected to be high during the forecast period. Moreover, players with a larger product portfolio and significant R&D investments create strong competition in the global market. Some of the top companies operating in the market include DermTech Inc, Michelson Diagnostics Ltd, NeraCare GmbH, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS
    • 2.5.2. EXPANDING DEMAND FOR SKIN CANCER DIAGNOSTICS IN AUSTRALIA

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. INCREASING PREVALENCE OF SKIN CANCER
    • 3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
    • 3.2.2. STRINGENT REGULATORY FRAMEWORK
    • 3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PARENT MARKET ANALYSIS
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. GROWTH PROSPECT MAPPING
  • 4.5. MARKET CONCENTRATION ANALYSIS
  • 4.6. VALUE CHAIN ANALYSIS
    • 4.6.1. RESEARCH AND DEVELOPMENT
    • 4.6.2. MANUFACTURING
    • 4.6.3. MARKETING AND SALES
    • 4.6.4. DISTRIBUTION AND LOGISTICS
    • 4.6.5. TRAINING AND SUPPORT

5. MARKET BY TYPE

  • 5.1. MELANOMA
  • 5.2. NON-MELANOMA

6. MARKET BY GENDER

  • 6.1. MALE
  • 6.2. FEMALE

7. MARKET BY SCREENING TYPE

  • 7.1. SKIN BIOPSY
  • 7.2. DERMATOSCOPY
  • 7.3. LYMPH NODE
  • 7.4. BIOPSY IMAGING TESTS
  • 7.5. BLOOD TESTS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET DRIVERS
    • 8.1.3. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
    • 8.1.4. KEY PLAYERS IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.1.1. UNITED STATES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.1.5.2. CANADA
      • 8.1.5.2.1. CANADA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. EUROPE SKIN CANCER DIAGNOSTICS MARKET DRIVERS
    • 8.2.3. EUROPE SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
    • 8.2.4. KEY PLAYERS IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. UNITED KINGDOM
      • 8.2.5.1.1. UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.2. GERMANY
      • 8.2.5.2.1. GERMANY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.3. FRANCE
      • 8.2.5.3.1. FRANCE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.4. ITALY
      • 8.2.5.4.1. ITALY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.5. SPAIN
      • 8.2.5.5.1. SPAIN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.6. NORDIC COUNTRIES
      • 8.2.5.6.1. NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.7. BELGIUM
      • 8.2.5.7.1. BELGIUM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.8. POLAND
      • 8.2.5.8.1. POLAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.2.5.9. REST OF EUROPE
      • 8.2.5.9.1. REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET DRIVERS
    • 8.3.3. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
    • 8.3.4. KEY PLAYERS IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.1.1. CHINA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.2. JAPAN
      • 8.3.5.2.1. JAPAN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.3. INDIA
      • 8.3.5.3.1. INDIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.4. SOUTH KOREA
      • 8.3.5.4.1. SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.5. INDONESIA
      • 8.3.5.5.1. INDONESIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.6. THAILAND
      • 8.3.5.6.1. THAILAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.7. VIETNAM
      • 8.3.5.7.1. VIETNAM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.8. AUSTRALIA & NEW ZEALAND
      • 8.3.5.8.1. AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.3.5.9. REST OF ASIA-PACIFIC
      • 8.3.5.9.1. REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET DRIVERS
    • 8.4.3. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
    • 8.4.4. KEY PLAYERS IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.1.1. LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
      • 8.4.5.2. MIDDLE EAST & AFRICA
      • 8.4.5.2.1. MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.2. PARTNERSHIPS & AGREEMENTS
  • 9.2. COMPANY PROFILES
    • 9.2.1. AMLO BIOSCIENCES LIMITED
    • 9.2.2. BIOMERIEUX SA
    • 9.2.3. CASTLE BIOSCIENCES INC
    • 9.2.4. DERMLITE LLC
    • 9.2.5. DERMTECH INC
    • 9.2.6. F. HOFFMANN-LA ROCHE LTD
    • 9.2.7. MICHELSON DIAGNOSTICS LTD
    • 9.2.8. NERACARE GMBH
    • 9.2.9. SKYLINEDX BV
    • 9.2.10. VERISKIN INC